Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Last 12 months price action with 12-month analyst target path
As of March 2, 2026, Harmony Biosciences Holdings, Inc. (HRMY) has a Wall Street consensus price target of $48.17, based on estimates from 13 covering analysts. With the stock currently trading at $28.54, this represents a potential upside of +68.8%. The company has a market capitalization of $1.65B.
Analyst price targets range from a low of $31.00 to a high of $62.00, representing a 64% spread in expectations. The median target of $48.00 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 10 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 2 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, HRMY trades at a trailing P/E of 10.5x and forward P/E of 8.0x. Analysts expect EPS to grow +31.4% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $46.95, with bear and bull scenarios of $-3510.31 and $86.61 respectively. Model confidence stands at 37/100, suggesting limited visibility into future performance.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how HRMY stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonThe consensus Wall Street price target for HRMY is $48.17, representing 68.8% upside from the current price of $28.54. With 13 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
HRMY has a consensus rating of "Buy" based on 13 Wall Street analysts. The rating breakdown is predominantly bullish, with 10 Buy/Strong Buy ratings. The consensus 12-month price target of $48.17 implies 68.8% upside from current levels.
With a forward P/E of 8.0354x, HRMY trades at a relatively low valuation. The consensus target of $48.17 implies 68.8% appreciation, suggesting meaningful undervaluation.
The most bullish Wall Street analyst has a price target of $62 for HRMY, while the most conservative target is $31. The consensus of $48.17 represents the median expectation. Our quantitative valuation model projects a bull case target of $87 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
HRMY is moderately covered, with 13 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 10 have Buy ratings, 1 recommend Hold, and 2 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month HRMY stock forecast based on 13 Wall Street analysts shows a consensus price target of $48.17, with estimates ranging from $31 (bear case) to $62 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $47, with bear/bull scenarios of $-3510/$87.
Our quantitative valuation model calculates HRMY's fair value at $47 (base case), with a bear case of $-3510 and bull case of $87. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 37/100.
HRMY trades at a forward P/E ratio of 8.0x based on next-twelve-months earnings estimates compared to a trailing P/E of 10.5x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are very optimistic on HRMY, with a "Buy" consensus rating and $48.17 price target (68.8% upside). 10 of 13 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
HRMY analyst price targets range from $31 to $62, a 64% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $48.17 consensus represents the middle ground. Our model's $-3510-$87 range provides an independent fundamental perspective.